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Abstract  
A composite is a material made of more than one component, and the bond between the 
components is on a scale larger than the atomic scale. The objective of the present study was 
to synthesize and perform the structural characterization and biological evaluation of a new 
biocomposite (BCO) based on a novel combination of an organic and an inorganic phase, for 
bone tissue engineering applications. The organic phase consisted of Wharton’s Jelly (WJ), 
which was obtained from embryonic tissue following a protocol developed by our laboratory. 
The inorganic phase consisted of bioceramic particles (BC), produced by sintering 
hydroxyapatite (HA) with β- tricalcium phosphate (β-TCP), and bioactive glass particles (BG). 
Each phase of the BCO was fully characterized by SEM, EDS, XRD and FTIR. 
Biocompatibility was evaluated in vivo in the tibiae of Wistar rats (n=40). Histological 
evaluation was performed at 0, 1, 7, 14, 30 and 60 days. XRD showed the phases 
corresponding to HA and β-TCP, whereas diffractogram of BG showed it to have an 
amorphous structure. EDS showed mainly Si and Na, Ca, P in BG, and Ca and P in HA and 
β-TCP. FTIR identified bonds between the organic and inorganic phases. From a mechanical 
viewpoint, the composite showed high flexural strength of 40.3±0.8MPa. The synthesized 
BCO exhibited adequate biocompatibility as shown by formation of lamellar type bone 
linked by BG and BC particles. The biomaterial presented here showed excellent mechanical 
and biocompatibility properties for its potential clinical use.  
 
Keywords: Biocomposite, Biomaterial, Wharton’s Jelly, Bone regeneration, Biomimetic 
material 
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1. Introduction 
Bone tissue can be injured in a variety of clinical situations (cysts, tumors, trauma or hormonal 
diseases) generating bone defects, which can be repaired by the body [1].
 
However, when the 
defect exceeds a certain critical size, the repair process is affected, and bone tissue engineering is 
necessary [2, 3]. Bone tissue engineering is based on three pillars: the use of three-dimensional 
scaffolds, biomolecular signals, and cells. The ultimate goal of bone tissue engineering is to 
develop bony tissues on tissue engineered constructs that mimic the native bone. Scaffolds are 
the basis of bone tissue engineering (BTE), and are designed to interact with body tissues to 
produce a specific response and provide an ideal environment for bone formation. They must 
allow cell adhesion and proliferation, be replaced by the host tissue, have adequate mechanical 
behavior, and produce no immune response in the patient [2-4]. Seventy percent of bone consists 
of minerals, and 30% is organic material [5]. The inorganic phase consists of hydroxyapatite 
(HA) [Ca10(PO4)6(OH)2], a calcium phosphate salt, which provides bone with hardness and 
strength, whereas the organic phase mainly consists of type I collagen, which provides tensile 
and flexural strength.  
At present, most research on the synthesis of scaffolds focuses on the use of composite materials 
known as biocomposites (BCO), which consist of an organic and an inorganic phase in order to 
mimic the bone tissue structure (biomimetic concept) [6]. Such scaffolds not only mimic the 
extracellular matrix of bone, but also combine the inherent intrinsic advantages while 
minimizing the drawbacks of each phase. The organic phase can consist of natural or synthetic 
polymers. It must be pointed out, however, that polymers have poor mechanical performance in 
practical clinical applications. Natural polymers such as polysaccharides (alginate, chitosan, or 
various cellulose compounds) and protein (collagen, silk) are most commonly used today
 
[7-9].  
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The use of Wharton’s Jelly (WJ) as the organic phase would enhance the regenerative capacity 
of the tissue [10]. WJ consists mostly of collagen, glycosaminoglycans (GAGs) (mainly 
hyaluronic acid and chondroitin sulfate) and growth factors, providing a temporary anchorage for 
the three-dimensional adhesion, proliferation and differentiation of cells. WJ forms a hydrogel 
that provides a suitable platform for intercellular communication, matrix-cell-biomaterial 
interactions, and secretion of signaling molecules, which are responsible for directing the 
regenerative process [10].   
The most frequently used components for the inorganic phase are bioceramic (BC) and bioactive 
glass particles (BG), both of which are known for their osteoconductive properties. The 
degradation rate of BC matches the growth rate of the target tissue [11-13].  As regards BG, this 
biomaterial has the ability to form HA on its surface, forming chemical bonding with the bone 
tissue, and to stimulate certain genes, increasing the population of osteoblasts at the bone defect 
site [12-16]. The rationale for combining both biomaterials was that silica-calcium phosphate-
based compounds have a pro-osteogenic effect on bone cells, improving cell attachment and 
proliferation [17]. The release of calcium, phosphorus, and silica ions into the biological 
environment generates an increase in mRNA expression of osteocalcin and osteopontin in 
osteoblastic cells, and produces a significant increase in alkaline phosphatase activity [18]. 
Silica, in turn, plays an important role in bone marrow cell differentiation, increasing the 
phenotypic expression of osteoblasts [19]. In addition, it has been demonstrated that this type of 
implant coating induces higher protein adsorption, enhancing bone integration while minimizing 
the induction of inflammatory responses [20]. 
The aforementioned issues prompted the present work, in which a novel use of WJ as a three-
dimensional matrix in combination with BC (HA and β- tricalcium phosphate, β-TCP) and BG 
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particles, is proposed. This kind of combination would generate a synergistic effect resulting in a 
bone-like tissue, enhancing the biological and mechanical behavior of BCO.  
The objective of this work was to synthesize and perform the structural characterization and 
biological evaluation of a new WJ-BC-BG-based biocomposite for bone tissue engineering, 
which has the ability to facilitate bone tissue regeneration.  
 
2. Materials and Methods 
The BCO presented herein is made of BC (HA + β-TCP) and BG particles as the inorganic 
phase, and of WJ acting as a three-dimensional organic matrix (Fig. 1).   
2. 1 Obtaining the biocomposite (BCO) 
2.1.1 Synthesis of the Bioceramic (BC) 
HA was obtained from bovine bone, in keeping with the current rules and regulations of the 
Argentine National Agricultural Health Service (SENASA) and in compliance with 
traceability regulations,
 
 using specific methods for inactivation and removal of infectious 
agents (Committee for Proprietary Veterinary and Medicinal Products), and removal of bone 
marrow, blood and fat. The bone was cut into 5-20cm
3
 pieces. In order to remove 
hemoglobin and adipose tissue, 10kg of bone were placed in 20-liter buckets and washed six 
times by successive immersion for 48 hours in aqueous solutions of ammonium bicarbonate 
(0.2 % in wt.), sodium hydroxide (0.2 % in wt.), hydrogen peroxide (0.3 % in wt.), and 
glacial acetic acid (100 % in wt. of bone), using fresh solutions each time; the solutions were 
maintained at a constant temperature between 55-60ºC using an electric immersion heater.  
The degreased and blood-free bone was dried under forced hot air flow (using a centrifugal 
blower) inside a vertical metal muffle equipped with electric heaters. As a result, white 
spongy cortical bone was obtained. As shown by XRD analysis, it was composed only of 
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HA. The obtained material was dry ground in a ball mill (in a 10-liter porcelain pot, 
employing 1” diameter AISI 420 hardened steel balls) for 5 h. The powder was sieved 
manually to separate the particle fraction of less than 45 µm in size (ASTM#325) in 
agreement with standard ISO 13779-6: 2015 (Implants for surgery -- Hydroxyapatite -- Part 6: 
Powders). The grains of β-TCP were synthesized by wet precipitation [21], by addition of an 
acid solution of H3PO4 to a suspension of Ca(OH)2 (Merck, Germany; both chemicals were of 
analytical grade) at pH 6 and 22 °C, under constant agitation. The precipitate was composed 
mainly of calcium deficient HA, which was filtered, oven dried, and sintered at 1100°C for 2 h, 
in order to promote transformation into crystalline β-TCP. The presence of β-TCP phase and the 
degree of crystallinity were verified by X-ray diffraction (XRD), in agreement with standard ISO 
13175-3: 2012 (Implants for surgery--Calcium phosphates--Part 3: Hydroxyapatite and beta-
tricalcium phosphate bone substitute). The fractions smaller than 45 µm of β- TCP particles were 
also separated.  
For blending, 480g of HA powder, 60g of beta-TCP powder, and 250g of ethyl alcohol (95% 
v/v) were placed in 2-liter liquid-tight PVC jars and mixed using 10 to 15 (¾- 1 inch) porcelain 
balls as the grinding medium. The jars were placed horizontally on the rollers and rotated at 150 
rpm for 3 hours. The obtained slurry and the balls were placed in stainless steel bowls and dried 
in an electric oven at 70ºC for 3 hours; the mixture was then placed in the jars and milled gently, 
and the balls were removed from the powder by hand. The obtained powder was dispersed in a 
15 % (in wt.) aqueous solution of egg albumin, in a 1: 1 solid//liquid ratio, which was 
homogenized by stirring at 300 r.p.m. for 10 min. The viscous fluid was cast into silicone rubber 
molds, which were wrapped in PVC film and subjected to heating at 90°C in a thermostatic bath 
for 1 h. The gelled pieces (5 x 10 x 50 mm
3
) were oven dried and then placed in an electric 
furnace and heated at a rate of 10°C min
-1
 up to a sintering temperature of 1200°C and 
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maintained at that temperature for 2 h. Finally, the samples were cooled to room temperature at a 
slow rate. The product was ground and sieved to retain particles in the range of 150-350 µm. 
2.1.2 Synthesis of bioactive glass (BG) 
BG was obtained by mixing 45g of SiO2, 43.32g of CaCO3, 38.01g of Na2CO3, 30.27g of 
Na2HPO4.2H2O powders (Anedra, Argentine; all were analytical grade compounds) in a ball 
mill. This formulation was chosen to obtain a composition similar to 45S5 Bioglass
TM
, as 
confirmed by atomic absorption analysis. The mixture was subjected to a thermal cycle in an 
electric furnace in air employing a 500 cm
3
 Pt crucible. The cycle consisted of heating at 10°C 
min
-1
 up to 1350°C (well above glass melting point, which is close to 890°C), and maintaining 
the mixture at that temperature for 2h. The molten material was cast onto a steel plate to produce 
rapid quenching. This process was repeated twice in order to guarantee composition 
homogeneity. BG particles were obtained by crushing and grinding a block of BG, and sieving to 
retain the 150-350 µm size fraction. 
 
2.1.3 Obtaining the Biological Matrix from Wharton’s Jelly (WJ) 
The matrix was extracted by processing Human Wharton's jelly following a proprietary method, 
currently at the stage of patent preparation, which involves a number of physicochemical steps. 
The placentas and umbilical cords were provided by the department of Gynaecology and 
Obstetrics of Prof. Dr. Ramón Carrillo Hospital for Acute Diseases, (Buenos Aires, Argentina) in 
keeping with a protocol approved by the Research Ethics Committee (N° 1339).  
Umbilical cords (approximately 20cm) were collected from seven patients at full term delivery, 
placed in transport medium (Hank’s Balanced Salt Solution supplemented with 
antimycotic−antibiotic solution, Invitrogen Life Technologies, CA, USA), stored at 4°C, and 
processed within 12h after collection. Each cord was cut into 2 cm long pieces, washed well in 
Page 7 of 35
John Wiley & Sons, Inc.
Journal of Biomedical Materials Research: Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
This article is protected by copyright. All rights reserved.
Novel biocomposite based on Wharton's Jelly 
 
 
8 
distilled water to remove blood and debris, and gently teased to squeeze out any trapped blood 
inside the veins and arteries. Each piece was cut open lengthwise with sterile scissors, and placed 
with its inner surface facing down in a 60 mm Petri dish in order to extract WJ. The material was 
subjected to several chemical processes (which will be described in the future patent), preserving 
the neutrality of the obtained WJ water solution. Finally, the solution was granulated in a spray 
dryer and maintained below 42°C. The entire process was conducted in a sterile area of a 
pharmacological laboratory, following a strict microbiological protocol to avoid contamination 
with pyrogens. WJ was sterile-packaged and stored in vacuum until use.  
2.1.4 Obtaining the Biocomposite   
The inorganic phase was a mixture of 20g of BG (5% of total weight) and 400g of BC (95% of 
total weight). The organic phase was obtained by dissolving WJ granules in bi-distilled water at 
10% (in wt.) at 25°C under constant stirring. The BCO were obtained by dispersion of inorganic 
particles in WJ solution in a 1:3 ratio (in wt.%). In order to perform mechanical tests and to 
prepare the micro implants, the viscous fluid was injected into rubber molds with 5x10x50mm
3 
wells using a 60 cm
3
glass syringe without needle in order to prevent the dispersed particles 
from obstructing the flow. CO dehydration was performed under a forced flow of sterile filtered 
air in a 4” diameter glass tube for 48 hours, in order to obtain stiff pieces that would not lose 
their shape. The pieces were wrapped in surgical paper and polyethylene bags, and sterilized by 
gamma irradiation at a dose of 10 kGy.  
The stiffness of BCO pieces was suitable for cutting with a manual saw to obtain 5x10x50mm
3 
samples for the mechanical tests. Laminar implants measuring 6.0x1.0x1.0mm
3
 were obtained to 
assess biological response.   
2.2 Structural, mechanical and biochemical characterization  
The microstructure of the BC, the BG and BCO was analyzed by scanning electron microscopy 
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(SEM, Zeiss Supra model 40, Germany), and local chemical analysis was performed by Energy- 
dispersive X-ray spectroscopy (EDS, Oxford Instruments, UK). Identification of the crystalline 
phases was performed by X-ray diffraction (XRD, Rigaku, Japan) using CuKα radiation (λCuKα 
= 0.1542 nm) with Ni filter, in a vertical goniometer, with 2θ scanning angle range of 20 -70° 
and a step size of 0.2 °. The chemical nature of bonds was studied by infrared Fourier transform 
spectroscopy (FTIR, Perkin-Elmer, model Frontier®, USA) in Attenuated Total Reflectance 
(ATR) mode, registering at 4 cm
-1
 resolution averaging 50 scans over a range of wavenumbers 
400 cm
-1
 to 4000 cm
-1
. 
Mechanical strength was assessed by using a three-point bending test on 20 BCO samples 
measuring 5x10x50mm
3
. The measurements were made in a universal testing machine (Instron 
5960, USA) under a load of 500 N and at a crosshead speed of 1 mm/min, until fracture 
following plastic deformation. Flexural strength, σf (in MPa), was determined using the 
following equation:  
σf = 3 FL/2bd
2 
F is the load at a given point on the load deflection curve, (N) L is the support span, 25 (mm), b 
is the width of test beam (in mm), and d is the depth or thickness of tested beam, (mm). 
The flexural modulus, E f ,  wa s  calculated as follows:  
E f= Lm/4bd
3                                                                                               
(2) 
m is the slope of the initial straight-line portion of the load deflection curve, (N/mm). 
 
 
2.3 In vivo bioassays  
Male Wistar rats (n= 60, mean body weight: 150g) were used in order to study biological 
response to BCO. The animals were fed ad libitum. All animal procedures were performed in 
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accordance with the guidelines of the National Institutes of Health  (NIH Publication - Guide for 
the Care and Use of Laboratory Animals: Eighth Edition (2011) and the guidelines of the School 
of Dentistry, Buenos Aires University (Res (CD) 352/02 y Res (CD) 694/02) for the care and use 
of laboratory animals. 
The animals were anesthetized intraperitoneally with a solution of 8 mg of ketamine 
chlorhydrate (Fort Dodge®, Argentine) and 1.28 mg of Xylazine (Bayer, Germany) per 100 mg 
of body weight. The skin of both tibiae was shaved prior to performing a 1.5 cm incision along 
the tibial crest. The subcutaneous tissue, muscles and ligament were dissected to expose the 
lateral external surface of the diaphyseal bone. A hole measuring 1.5 mm in diameter was made 
in the bone with an end-cutting bur, using manual rotating movements to avoid overheating and 
necrosis of the bone tissue. BCO implants (6.0x1.0x1.0mm
3
) were placed in the hematopoietic 
bone marrow compartment of both tibiae, parallel to their longest axis. A separate-stitch suture 
was performed. No antibiotic therapy was administered [22].  
The animals were euthanized in groups of 10 by an overdose of anesthetic at 0, 1, 7, 14, 30 and 
60 days post-implantation. The tibiae were resected, fixed in 10% formalin solution, and 
radiographed. One group of samples was demineralized in 7% nitric acid (Anhedra, Argentina), 
embedded in paraffin, and stained with H-E. The remaining group was embedded in methyl-
methacrylate. The samples were then sectioned using a diamond saw (EXAKT Apparatebau, 
Germany) and three slices were cut at approximately 500µm, perpendicular to the longest axis of 
the tibiae, that is, through the middle of the implant bed and at two points equidistant from the 
middle. The cross-sections were ground using a grinding machine and finished manually with 
sandpaper. Sections about 70µm thick were stained with 1% toluidine blue and mounted on glass 
slides and coverslipped for histological analysis. The samples were examined using conventional 
and polarized light microscopy.  
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Histomorphometric determinations were performed to assess the area of newly formed lamellar 
bone in contact with the particles of the biocomposite with respect to the total area (40X). 
Histomorphometric measures were determined on digitized images of histological sections 
obtained 30 and 60 days post- implantation of the biomaterial into the tibia of Wistar rats. The 
images were obtained using a light microscope (Axioskop 2 MOT, Carl Zeiss, Jena, Germany) at 
40X magnification, and they were analyzed histomorphometrically using Image Pro Plus 
software (Version 6.0) (Mediacybernetics Rockville, USA). The results were compared using 
Student’s t-test. Values are expressed as mean and SD; statistical signiﬁcance was set at P<0.05. 
A set of sections was coated with a thin (20-nm) layer of silver in a vacuum evaporator, for SEM 
and EDS.  
 
3. Results  
3.1 Structural, mechanical and biochemical Characterization  
As shown by SEM, the surface of the BCO after molding and in a dehydrated state was uneven 
and non-porous (Fig. 2.A) since the WJ covered the entire surface of the BCO during the 
manufacturing process. Higher magnification allowed observation of the fibrous structure of the 
WJ, with randomly arranged collagen bundles forming a complex net-like structure (Fig. 2.B). 
Analysis of cross sections of samples embedded in methyl-methacrylate observed by SEM 
showed BG and BC particles inside the newly formed bone (Fig. 2.C and 2.D). 
EDS of histological sections showed mainly Si, Na, Ca, and P in BG, and Ca and P in HA and 
β-TCP (Fig. 2.D and 2.E). SEM images and EDS spectra clearly showed the presence of BG in 
the BCO, even when the concentration of BG was low (5% of total weight) (Fig. 2.D). 
XRD analysis of the BC and BG confirmed their crystalline and amorphous nature respectively 
(Fig. 3). The BC was composed of HA (file 34-0010) and β-TCP (file 55-0898) phases. The BG, 
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however, showed a single broad peak centered at 31.8° corresponding to SiO2 (file 05-0492) 
[ICD05], with no evidence of other oxides, as shown by EDS and as observed in all bioactive 
glasses [23, 24]. 
Analysis of FTIR spectra of BC showed predominant presence of the PO4
3-
 group in the 960-
1109 cm
-1 
band, and 602, 565 and 475 cm
-1
 [25, 26]; whereas the OH
 
group was found in 3573 
cm
-1
 [25-29], and 872 and 631cm
-1
 [29]. In contrast, the spectrum of BG exhibited only a few 
peaks, which could be associated with the nominal composition of Bioglass
TM
, despite the 
spectrum being rich in absorption peaks (Fig. 4). Vibrations of the PO2 group could be observed 
at 1416 and 1445 cm
-1
 [30], and a small intensity peak of PO vibration could be observed at 
595cm
-1
 [31]. Vibrations associated with Si-O-Si amorphous silicate were detected at 1092 and 
451 cm
-1
 [30, 31].  
The biological matrix has amide functional groups, which are characteristic of collagen type I 
and II polypeptides (Fig. 4). Hence, amide I was present at 1656 and 1159cm
-1
 [26-38], amide II 
was observed at 1539cm
-1 
[35-36], amide III at 1452 and 1244cm
-1
 [34-42], amide A at  3468cm
-
1
 [36, 37] and amide B at 2968cm
-1
 [34-40]. Other functional groups (CH3, CH2, CH) may have 
contributed to absorption at 1339cm
-1
 [42] (Fig. 4). The least clear association occurred at 
1090cm
-1
, which may correspond to the vibrational states of C-C and C-N [38] Nevertheless, 
these results would not be sufficient to say that the matrix was collagen, and likely corresponds 
to isolated poly-peptide chains, resulting from the denaturation caused by the chemical 
treatments to which the WJ was subjected.    
FTIR analysis of BCO showed overlapping of absorption peaks and bands of BC and biological 
matrix (WJ) phases, which were analyzed separately before BCO moulding (Fig. 4). The 
interaction between BC crystals and WJ, probably containing some amino acid residues of the 
poly-peptide chains, could be attributed to the phosphate band between 980 and 1150 cm
-1
 [34-
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42], whereas the 878cm
-1
 could be attributed to the carbonation of HA, which closely resembles 
that of natural bone tissue [43] (Fig. 4). The presence of BG in the BCO was not discernible in 
FTIR and XRD, because of the low concentration of BG (5% weight of inorganic phase). 
However, BG particles could be detected on SEM images and by EDS analysis of histological 
sections (Fig. 2D, 5, 6, 8). In addition, SEM images showed partially resorbed BC particles (Fig. 
2.D). 
Mechanical testing using the three point bending flexural test showed un-implanted dehydrated 
BCO blocks measuring 5x10x50mm
3 
to have a maximum flexural strength of (40.3±0.8) MPa, 
whereas the flexural modulus was (2.44±0.11) GPa. 
3.2 Biological response  
Paraffin embedded sections obtained at T0 (immediately post-implantation) showed negative 
spaces corresponding to the inorganic particles in the BCO, which were amalgamated by large 
basophilic areas corresponding to the organic matrix of the biomaterial (Fig. 5 A, B). At 24 h 
post-implantation (T1d), close contact between the BCO particles and the clot could be observed, 
evidencing the adequate wetting properties of the biomaterial. In addition, abundant 
polymorphonuclear neutrophils (PMNn) corresponding to the acute inflammatory infiltrate could 
be observed (Fig. 5 C, D).  
At 7 days post-implantation, formation of reparative granulation tissue with abundant fibroblasts 
in close contact with the BC and BG particles could be seen (Fig. 6 A-C). It is noteworthy that 
the organic matrix, made up of the WJ, was completely replaced with the reparative granulation 
tissue, and there was no evidence of inflammatory infiltrate at this time point. In addition, 
multinucleated giant cells could be seen at the center of the reparative tissue, but were not found 
at the later experimental times (Fig. 7). Fourteen days post-implantation, woven bone tissue (as 
confirmed by polarized light microscopy) could be observed amalgamating the BCO particles 
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(Fig. 6 D-F). At 30 and 60 days, the woven bone had been replaced with lamellar bone (as 
confirmed by polarized light), which formed bridges of bone linking the BC and BG particles. At 
30 and 60 days, the woven bone had been replaced with lamellar bone (as confirmed by 
polarized light), which formed bridges of bone linking the BC and BG particles. The lamellar 
bone exhibited the typical microstructure with collagen fibers arranged in parallel lamellae or in 
concentric layers around canals containing vessels, forming the Haversian-systems. Osteocyte-
containing lacunae were also observed between or inside the lamellae (Fig. 8).  
The BCO particles and their interface with the bone tissue could be observed on the methyl-
methacrylate embedded sections (image not shown).  
The histomorphometric studies showed the area of lamellar bone to increase with time. The area 
of newly formed bone was 26.517,65 ± 3.433,15 µm
2 
at 30 days
 
(T30) and 48.638,23 ± 3.736,77 
µm
2 
at 60 days (T60), in a total area of 90.000 µm
2
. The difference was statistically significant 
p<0.05.  
 
4. Discussion  
Bone can be considered a nano-composite material made up of collagen protein fibers threading 
through a HA mineral phase, which makes up about 60–70 wt% of the bone structure. Based on 
a biomimetic mechanism, we prepared a BCO with a biphasic organic/inorganic structure similar 
to that of natural bone.  
The organic phase of the BCO was WJ. The latter mainly consists of various isoforms of 
collagen and proteoglycans, enabling it to form a hydrogel and serve as a reservoir of numerous 
growth factors including TGF-B, IGF-I, FGF, EGF and PDGF [44-46].  
As shown by SEM, the WJ in the BCO consisted of collagen fibers forming a substantial three-
dimensional net-like structure that was similar to that described by other authors [47], and the 
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BG and BC particles were intertwined with the fibers.  
The wettability of BCO in a physiological environment is associated mainly with the presence of 
hydroxyl groups and negative charges in hyaluronic acid [46], which is one of the components of 
WJ and is used in the synthesis of biological scaffolds for wound-healing applications. This 
property leads to rapid hydrogel formation and haemoglobin colonization in the scaffold, from 
the first moment after implantation [47]. The histologic findings observed in the present study at 
the initial time points, soon after implantation of the BCO in the rat tibia, confirmed this 
phenomenon. 
There are reports on the use of collagen type I obtained from epidermal and bovine tendon or 
porcine tissue to make a matrix for BCO synthesis. This type of collagen is combined with BG 
[43, 48-53] and calcium phosphates, such HA [27, 34, 35, 54-59] and biphasic ceramics (HA 
plus β-TCP) [37-41, 60-61].The present study is the first to describe the novel use of WJ 
extracellular matrix as the organic phase of BCO providing a three-dimensional scaffold, which 
is a suitable platform for intercellular communication and biomaterial-cell interaction.  
Despite the numerous research groups devoted to investigating stem cells obtained for tissue 
engineering applications, to our knowledge there are no reports in the literature on the use of WJ 
as a scaffold [44, 46-48] 
XRD and FTIR analysis revealed that BC particles were composed of β-TCP and HA, whereas 
the BG exhibited the characteristics of an amorphous material. Moreover, the average size of the 
inorganic particles was 282±78µm, as confirmed on SEM images. This size range is considered 
ideal for osteogenesis [62].  
The FTIR spectrum of BCO had frequencies for amide A, B, I, and II bands; the intensity of the 
peaks would seemingly depend on BC content. All collagen amides showed a red shift (to lower 
wave number) when BC was added to the WJ, suggesting collagen-BC interactions. As 
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compared to the spectrum corresponding to WJ alone, the intensity of shifts of amides decreased 
as BC was added to the mixture, as follows: amide A decreased from 3468 to 3318 cm
-1
, amide 
B from 2968 to 2930 cm
-1
, whereas amide I shifted to a higher wave number from 1686 to 1656 
cm
-1
, amide II shifted from 1539 to 1537 -cm
-1
, and amide III disappeared. These results indicate 
that there is some degree of bonding between HA and collagen. The Ca
+2
 in the HA likely forms 
hydrogen bonds with the CONH and OH groups in the collagen. These bonds probably form 
with the proline and lysine in the collagen [58, 63]. 
The present work sought to develop a BCO with improved mechanical strengths for application 
in BTE in regions where the scaffolds are subjected to high levels of loading. A number of 
research groups have attempted to synthesize HA-collagen composites with adequate stiffness 
for clinical applications, but the obtained materials have shown poor mechanical properties [9, 
10]. This limited performance is a result of the procedure followed to obtain composite, 
precipitation of calcium phosphate on collagen fibers, since the process in itself does not ensure 
adequate bone architecture. Mittlmier and Nizzard [64] were among the first researchers to 
attempt to develop a collagen–calcium phosphate composite, by mixing calcium phosphate 
granules with collagen web. Other researchers obtained these composites by mixing the calcium 
phosphate granules in a collagen suspension. Overall, the aforementioned composites showed a 
lack of cohesive strength, and were not entirely suitable for manufacturing implants that could be 
easily handled by surgeons and that had adequate biological properties [27, 34, 35, 55-59, 64]. 
It is possible that the presence of fragments of hyaluronic acid (HAc) in WJ contributes to 
increasing the cohesion among the components of the biomaterial. The dry stage (previous to 
implantation) BCO WJ-BC-BG flexural strength was close to (40.3±0.8) MPa and its flexural 
modulus was (2.44±0.11) GPa, which is in the range of the best mechanical performance of 
calcium phosphate-collagen composites reported in the literature [49,59]. Nevertheless, these 
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values are still far from the mechanical performance of healthy bone. Femoral bone has an 
ultimate flexural strength of (179.6 ± 19.4) MPa, and its flexural modulus is (10.8 ± 1.9) GPa 
(4.5-fold higher than that of the BCO presented here).  
The best tensile strength magnitude reported to date is 96MPa, and corresponds to a composite 
containing up to 5% (in wt) hyaluronic acid (HAc) (80HA-15Coll-5HAc). This value was 
found to decrease to 19MPa when the HAc content of the composite was 0.8% [47]. It must be 
kept in mind, however, that these composites were obtained by compression moulding and 
heating at 200°C. It is likely that the collagen and HAc molecules became denatured at that 
temperature, thus affecting the biological response to the BCO. In addition, cross-linking 
collagen with glutaraldehyde in hot-pressed composites yields a bending strength of 21MPa, as 
does a high HA content (up to 80% in wt.) [55]. Crosslinking can be based on the formation of 
hydrogen bonds between collagen molecule chains and HA and β-TCP functional groups. This 
shows the importance of the molecular geometry as regards strength, toughness and energy 
dissipation properties [63]. In addition, it has been shown that there are complex crosslinks 
between calcium ions and the oxygen atoms in the proline amino acid [58-63]. The mechanical 
strength of BCO can be interpreted within the framework of qualitative and quantitative 
toughness studies of HA-collagen composites. A previous work reported mechanical strength 
of the composite to be higher than that of individual phases [28].  In addition, Young's 
modulus of pure HA was 3.6GPa [57], whereas incubation of HA in collagen solution 
increased the magnitude to 7.5GPa. In order to assess the mechanical properties of a BCO, 
toughness of the HA-collagen composite itself must be assessed both qualitative and 
quantitatively, since the values obtained assessing each composite component separately are 
far lower than those observed when testing the composite. In line with studies reported in the 
literature, the compressive modulus of collagen scaffolds was found to increase 10-fold (from 
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20 to 200 KPa) when increasing HA particle content from 50 to 400% (in wt.) [63, 64].  
The biological response to this novel BCO was evaluated in vivo. The interaction between the 
surface of the biomaterial and the biological environment plays a fundamental role in the host’s 
response. Our results showed that the BCO formed a hydrogel on its surface. Recent studies have 
demonstrated that matrices that generate hydrogels favor vasculogenesis [65]. In addition, a 
number of studies have shown that BG and BC promote neovessel formation both in vitro and in 
vivo, and are therefore suitable for application in bone tissue engineering [66, 67]. Within the 
first 24 hours post-implantation, the blood clot could be seen in close contact with the 
biomaterial, as well as acute inflammatory infiltrate surrounding the BC and BG particles. Our 
observation is in agreement with a study by Tapetyet al in deproteinized bone (Bio-OssTM), 
though the authors found this to occur 3 days post-implantation [68]. The healing process was 
enhanced by the ability of the hydrogel to absorb large amounts of liquid and provide a suitable 
platform for intercellular communication [47]. Seven days after implantation, granulation tissue 
and multinucleated giant cells (MNGCs) could be observed in some areas of the tissue. These 
cells were no longer observed 14 days post-implantation. In contrast with what was previously 
thought [69], it is well documented at present that MNGCs stimulate vasculogenesis and 
angiogenesis through the release of different chemical mediators, such as vascular endothelial 
growth factor (VEGF) [70, 71]. In their study on biological response to small Bio-OssTM 
particles, Barbecket al. detected MNGCs between days 10 and 15 post-implantation, and found 
the number of these cells to decrease towards 30 days post-placement, with only few remaining 
at 60 days [70, 71]. The finding of MNGCs does not necessarily imply a negative response of the 
host to the biomaterial, and must be evaluated in terms of the persistence of these cells through 
time, since their presence can have a positive effect on vascularization and the healing process.  
No inflammatory infiltrate and no MNGCs were observed 14 days post-implantation, and woven 
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bone was found amalgamating the BG and BC particles. The high biocompatibility of the 
inorganic components (BG and BC) is well documented [2-8, 12-16]. Hench et al showed the 
ability of BG to form HA on its surface and promote differentiation of undifferentiated 
mesenchymal cells into osteoblasts [12-16]. Polak et al. demonstrated the ability of BG to 
stimulate seven specific genes to increase the population of osteoblasts at the biomaterial 
implantation site, as a result of the release of ionic products [15]. As regards BC, in addition to 
being osteoconductive, biphasic BC (HA + β-TCP) also promotes osteogenesis, and its 
degradation rate matches the growth rate of the target tissue [2, 3, 6, 12, 13].   
A number of authors have used stem cells derived from the umbilical cord, and have highlighted 
their osteogenic potential. Nevertheless, there are no reports on the use of WJ as a matrix for 
BCO [44, 46, 48]. WJ is a reservoir of growth factors and mainly consists of collagen, hyaluronic 
acid, and sulfated glycosaminoglycans (GAGs). The latter play an important role in cell-cell and 
cell-extracellular matrix interactions. Rodrigues et al. found that the collagen (COL) in a HA-
COL composite provides binding sites for growth factors, and improves the mechanical 
properties of the biomaterial [72]. 
Thirty days post-implantation, the woven bone had been replaced with lamellar bone, which can 
satisfactorily meet its mechanical demands [57]. All the aforementioned findings show the high 
biocompatibility and osteogenic capacity of the new biomaterial proposed herein.  
 
5. Conclusions 
A novel biocomposite (BCO) was synthesized and characterized. The biocomposite is based on 
the combination of Wharton’s Jelly (WJ), as the organic matrix, and inorganic bioceramic (BC) 
and bioactive glass (BG) particles. The synthesized composite, which has not been described in 
the literature to date, showed high toughness and was suitable for tissue regeneration and 
lamellar bone formation. The newly formed lamellar bone was found to form bridges 
Page 19 of 35
John Wiley & Sons, Inc.
Journal of Biomedical Materials Research: Part A
1
2
3
4
5
6
7
8
9
10
11
12
13
14
This article is protected by copyright. All rights reserved.
Novel biocomposite based on Wharton's Jelly 
 
 
20 
amalgamating the inorganic particles, which is of utmost importance from the biomechanical 
point of view. The physical-chemical properties of BCO and the observed biological response to 
this biocomposite render it suitable for clinical applications. 
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Schematic drawing of the Biocomposite and its components  
Fig. 1  
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Fig. 2. SEM images of the dehydrated biocomposite (BCO) (A), dehydrated Wharton Jelly (WJ) (B) and 
methyl-methacrylate histological sections (C, D); C and D also show microchemical analysis (EDS). A) 
Uneven non-porous surface of the BCO. B) Complex net-like structure of the dehydrated WJ. C) Bone tissue 
around a BG particle. The spectrum shows the peaks corresponding to the main components of the BG (Si, 
Mg, Na and Ca). D) Newly formed bone tissue in contact with the BC particles. The spectrum shows the 
peaks corresponding to the main components of the BC (Ca and P).  
Fig 02  
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Fig. 3. Diffractograms of BC (above) and BG (below).  
Fig. 03  
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FTIR spectra of BC (top left), FTIR spectra of BG (top right), FTIR spectra of WJ (bottom left) and FTIR 
spectra of BCO (bottom right).  
Fig. 4  
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Fig. 5. Histological study at T0 (A and B) andT1d (C and D). A) BCO inside the medullary compartment and 
surrounded by the blood clot (c); note the inorganic particles (υ) amalgamated by the organic matrix of the 
biomaterial (∀). B) Bioactive glass (*) and BC particles (#) are surrounded by organic matrix (∀). A) Orig 
Mag X100. B) Orig. Mag. X400. H-E Stain. C) BC (#) surrounded by the blood clot (c). D) Visualization of a 
BG particle (*) surrounded by the clot (c) and cells of the acute inflammatory infiltrate. C) Orig. Mag. X400. 
D) Orig. Mag. X1000. H-E Stain.  
Fig. 05  
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Fig. 6. Histological study at T7 (A-C) and T14d (D-F). A-C show inorganic particles (υ) surrounded by 
reparative granulation tissue with abundant fibroblasts. A) Orig. Mag. X100. B) Orig. Mag. X400 C) Orig. 
Mag. X1000. H-E Stain. D-F show inorganic particles surrounded by woven bone tissue at 14 days. E) Note 
the presence of a BG (*) particle and D and F BC particles (#). D-F  Orig. Mag. X400 H-E Stain.  
Fig. 06  
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Fig. 7. Histologic study at T7d. Abundant multinucleated giant cells (►) can be seen at the center of the 
reparative granulation tissue. Orig. Mag. X400. H-E Stain.  
Fig. 07  
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Fig. 8. Histologic study at T30d. A) Abundant BC particles (#) and a BG particle (*) are surrounded by 
lamellar bone. B) Note the presence of lamellar bone and parallel alignment of collagen fibers, as seen using 
polarized light (C). D) A BG particle (*) surrounded by lamellar bone, as seen using polarized light (E). A- 
Orig. Mag. X100. B- E Orig. Mag. X400. H-E Stain. F) Bone tissue section showing the microstructure of 
lamellar bone. Note the presence of osteocytic lacunae containing osteocytes (→), Haversian-systems (▲), 
and a large number of incremental lines (↓↓). G) Bone tissue section shown in microphotograph (F) as seen 
under polarized light. Note the parallel alignment of collagen fibers forming the lamellae of lamellar bone 
(↓). A: Orig. Mag. X100; B-G: Orig. Mag. X400. H-E Stain.  
Fig. 08  
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